Table 1 Clinical and pathological characteristics of the 102 patients analysed in the discovery (n=72) and the validation sets (n=30)

From: Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers

Characteristics

Discovery set ( n =72)

Validation set ( n =30)

Agea

61.5 (24–88)

56 (36–78)

 

N (%)

N (%)

Histology

  

 LGSCb

2 (2.8)

1 (3.3)

 HGSC

36 (50)

15 (50)

 Endometrioid

13 (18)

8 (26.7)

 Mixed

8 (11.1)

—

 Clear cell

7 (9.7)

5 (16.7)

 Mucinous

3 (4.2)

1 (3.3)

 Undifferentiated

3 (4.2)

—

FIGO stage

  

 Early stage

  

I

11 (15.2)

6 (20)

IIA

2 (2.8)

1 (3.3)

IIB

2 (2.8)

—

 Advanced stage

  

IIC

6 (8.3)

3 (10)

III

39 (54.2)

17 (56.7)

IV

12 (16.7)

3 (10)

Response to therapy

  

 Resistantc

13 (18)

5 (16.7)

 Sensitive

53 (73.6)

23 (76.6)

 No CT

4 (5.6)

2 (6.7)

 N/A

2 (2.8)

—

  1. Abbreviations: CT = chemotherapy; FIGO = Fédération Internationale de Gynécologie et d'Obstétrique; HGSC=high-grade serum carcinoma; LGSC=low-grade serum carcinoma; N/A = Not Available.
  2. aMedian and range are reported.
  3. bBoth of which were advanced-stage lesions.
  4. cPatients were classified as platinum-resistant if they developed progression or recurrence of disease in ⩽6 months from the completion of first-line chemotherapy (Therasse et al, 2000).
Back to article page